CFTR and cystic fibrosis: This qualitative study demonstrates initial content validity of the CF-IQ as a standardized PRO assessment tool for evaluating the impacts of CF, extending the scope of previous instruments to more sensitively quantify the burden of CF in patients treated with CFTR modulators and, thus, may offer a broader assessment of the efficacy of emerging therapies.